Compare NGVT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | XNCR |
|---|---|---|
| Founded | 1964 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2015 | 2013 |
| Metric | NGVT | XNCR |
|---|---|---|
| Price | $59.90 | $35.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $89.00 | $41.58 |
| AVG Volume (30 Days) | 293.3K | ★ 1.7M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.10 | ★ 65.36 |
| EPS | ★ 4.08 | N/A |
| Revenue | ★ $1,167,600,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | $18.52 |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | $18.07 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $46.38 | $10.38 |
| 52 Week High | $79.29 | $35.05 |
| Indicator | NGVT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 25.62 | 77.02 |
| Support Level | N/A | $11.05 |
| Resistance Level | $77.21 | N/A |
| Average True Range (ATR) | 2.66 | 2.04 |
| MACD | -0.98 | 0.92 |
| Stochastic Oscillator | 2.65 | 96.83 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.